Status:
UNKNOWN
Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
Lead Sponsor:
Cairo University
Conditions:
Metabolic Syndrome
Diabete Type 2
Eligibility:
All Genders
40-70 years
Phase:
PHASE4
Brief Summary
Several crosssectional and prospective studies have shown that metabolic syndrome and its related components are associated with both prevalent and incident CKD . Although the mechanisms for these ca...
Detailed Description
the current study is investigating the relation betweeneach componant of metabolic syndrome and kidney injury incidence or prevalence, and the mechanism of its occurence. the kidney protective effect ...
Eligibility Criteria
Inclusion
- men or women 40-70 years of age
- body mass index be-tween≥22 and ≤40 kg/m2.
- DM with an HbA1c ≥ 7
Exclusion
- (1) pregnant or nursing women; (2) chronic (\>7 consecutive days) oral, parenteral or intra-articular corticosteroid treatment within 8 weeks prior to Visit 1 (3) history or evidence of major hepatopathy (aspartate aminotransferase or alanineaminotransferase activities \> 2.5 times the upper limit of normal) (4) ischemic heart disease or cerebrovascular disease (5) creatinine level \> 0.133 mmol/L (6) major diabetes complications (chronic renal insufficiency, proliferative retinopathy and stroke); (7) extreme dyslipidemia, such as familial hypercholesterolaemia
- \-
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2020
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04485845
Start Date
November 1 2019
End Date
September 30 2020
Last Update
July 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Diabetes & Endocrinology Institute
Cairo, Egypt, 11311